35Pharma

About 35Pharma

35Pharma is a biopharmaceutical company dedicated to designing and developing best-in-class ligand traps targeting Activin x GDF biology to address diseases with high unmet medical needs, including pulmonary hypertension, heart failure, and obesity. The company leverages decades of experience in protein engineering to create innovative biologics with tailored multi-specificity and potency.

Products & Services

HS235:A lead candidate in clinical development (Phase I/II) for cardiometabolic disease and pulmonary hypertension. Designed to improve pulmonary and cardiac function while addressing metabolic health, targeting high unmet needs in pulmonary hypertension, heart failure, and obesity.

Specialties

Activin x GDF biology Ligand traps Protein engineering Pulmonary hypertension Heart failure Obesity Cardiometabolic disease

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 53000000 MR: - FA: 53 million FAN: 53000000	D: 2024-11-26 FD: 2024-11-26	10 investors

Series C Latest

2024-11-26

$53.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Ilia Tikhomirov

Chief Executive Officer

G

George Georges

Chief Medical Officer

M

Maureen O'Connor

Chief Scientific Officer

D

Dmitry Tikhomirov

EVP, Finance & Operations

M

Monique Champagne

VP, Clinical Operations

J

Julia Schoelermann

VP, Corporate Development

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

35Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised